GGrantIndex
← Leaderboards

Arthur Y Kim

Massachusetts General Hospital

$8,139,557
Attributed
$10,483,178
Total exposure
9
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,483,178 · 9

By mechanism

U19$5,146,586 · 5
R01$3,355,340 · 1
R56$837,583 · 1
K23$649,350 · 1
R21$494,319 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Hepatitis C Virus

Research focus

Hepatitis C VirusHepatitis CCohortImmuneResearch PersonnelPeripheral Blood Mononuclear CellImmune ResponseViralVirus DiseasesChronicSamplingPersonsInfectionVirusT-LymphocytePathogenInsightMassachusettsGeneticDatabasesRepositoryCollectionPlasmaClinical Data

Grant awards (35)

Core B: Clinical Core$352,588
U19 · FY2025 · AI · contact PI
Core B: Clinical Core$364,178
U19 · FY2024 · AI · contact PI
Core B: Clinical Core$236,477
U19 · FY2023 · AI · contact PI
Core B: Clinical Core$416,647
U19 · FY2022 · AI · contact PI
Core B: Clinical Core$295,684
U19 · FY2021 · AI · contact PI
Core B: Clinical Core$373,297
U19 · FY2020 · AI · contact PI
Core B: Clinical Core$326,686
U19 · FY2019 · AI · contact PI
Mitochondrial-Nuclear Genetic Interactions in Spontaneous HCV Clearance$205,450
R21 · FY2019 · AI
Tissue and Clinical Core$323,856
U19 · FY2018 · AI · contact PI
Mitochondrial-Nuclear Genetic Interactions in Spontaneous HCV Clearance$288,869
R21 · FY2018 · AI
Tissue and Clinical Core$319,456
U19 · FY2017 · AI · contact PI
Tissue and Clinical Core$214,234
U19 · FY2016 · AI · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$636,115
R01 · FY2015 · DA
Tissue and Clinical Core$284,557
U19 · FY2015 · AI · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$650,016
R01 · FY2014 · DA
Tissue and Clinical Core$226,634
U19 · FY2014 · AI · contact PI
Acute HCV in the prison population$154,499
U19 · FY2014 · AI · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$640,563
R01 · FY2013 · DA
Acute HCV in the prison population$145,232
U19 · FY2013 · AI · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$702,924
R01 · FY2012 · DA
Acute HCV in the prison population$156,624
U19 · FY2012 · AI · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$725,722
R01 · FY2011 · DA
Acute HCV in the prison population$160,747
U19 · FY2011 · AI · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$837,583
R56 · FY2010 · AI
Acute HCV in the prison population$166,220
U19 · FY2010 · AI · contact PI
Acute Hepatitis C Virus Infection in the Prison Population$130,669
U19 · FY2009 · AI · contact PI
Acute Hepatitis C Virus Infection in the Prison Population$127,822
U19 · FY2008 · AI · contact PI
Acute Hepatitis C Virus Infection in the Prison Population$133,219
U19 · FY2007 · AI · contact PI
Cell mediated Immunity to HCV in HIV+ Persons$129,870
K23 · FY2007 · AI · contact PI
Cell-mediated Immunity to HCV in HIV+ Persons$129,870
K23 · FY2006 · AI · contact PI
Acute HCV Infection in the Prison Population$124,812
U19 · FY2006 · AI · contact PI
Cell-mediated Immunity to HCV in HIV+ Persons$129,870
K23 · FY2005 · AI
Acute HCV Infection in the Prison Population$112,448
U19 · FY2005 · AI
Cell-mediated Immunity to HCV in HIV+ Persons$129,870
K23 · FY2004 · AI
Cell mediated Immunity to HCV in HIV+ Persons$129,870
K23 · FY2003 · AI